Education
About Us
Working with TipRanks
Follow Us
Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
BCAX Analyst Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BCAX Stock 12 Month Forecast
Average Price Target
$31.67
▲(75.94% Upside)
| Highest Price Target$48.00 | Average Price Target$31.67 | Lowest Price Target$8.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
―
Buy
―
Reiterated
09/30/25
Morgan Stanley
$36
Buy
100.00%
Upside
Reiterated
09/29/25
JonesTrading
$22
Buy
22.22%
Upside
Reiterated
09/29/25
Optimistic Buy Rating for Bicara Therapeutics: Superior Clinical Benefits and Valuation UpsideWe see a positive readthrough to BCAX from the acquisition of Merus (MRUS, Genmab (GMAB, Not Rated) for approx. $8bn (press release). The main driver of Merus' valuation is Petosemtamab (EGFR x LGR5), in pivotal Phase 3 trials in head and neck cancer. Bicara is a main competitor with ficerafusp alfa (FICERA; EGFR x TGF-β) and similar timeline towards potential FDA approval. We believe both drugs will get approved if they maintain similar levels of clinical benefits in Ph3 as seen in Ph1. Clinical data from Keytruda combo with Bicara's and Merus' bispecific candidates showed more than doubling of clinical benefits, and has started the race to the finish line. Though Bicara is approx. 6 months behind MRUS from the topline readout, we do not think this will be a winner take all situation.
H.C. Wainwright
$40
Buy
122.22%
Upside
Reiterated
09/17/25
Stifel Nicolaus
$48
Buy
166.67%
Upside
Reiterated
08/15/25
Wedbush
$30
Buy
66.67%
Upside
Reiterated
05/23/25
Rodman & Renshaw
$48
Buy
166.67%
Upside
Initiated
11/05/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
―
Buy
―
Reiterated
09/30/25
Morgan Stanley
$36
Buy
100.00%
Upside
Reiterated
09/29/25
JonesTrading
$22
Buy
22.22%
Upside
Reiterated
09/29/25
Optimistic Buy Rating for Bicara Therapeutics: Superior Clinical Benefits and Valuation UpsideWe see a positive readthrough to BCAX from the acquisition of Merus (MRUS, Genmab (GMAB, Not Rated) for approx. $8bn (press release). The main driver of Merus' valuation is Petosemtamab (EGFR x LGR5), in pivotal Phase 3 trials in head and neck cancer. Bicara is a main competitor with ficerafusp alfa (FICERA; EGFR x TGF-β) and similar timeline towards potential FDA approval. We believe both drugs will get approved if they maintain similar levels of clinical benefits in Ph3 as seen in Ph1. Clinical data from Keytruda combo with Bicara's and Merus' bispecific candidates showed more than doubling of clinical benefits, and has started the race to the finish line. Though Bicara is approx. 6 months behind MRUS from the topline readout, we do not think this will be a winner take all situation.
H.C. Wainwright
$40
Buy
122.22%
Upside
Reiterated
09/17/25
Stifel Nicolaus
$48
Buy
166.67%
Upside
Reiterated
08/15/25
Wedbush
$30
Buy
66.67%
Upside
Reiterated
05/23/25
Rodman & Renshaw
$48
Buy
166.67%
Upside
Initiated
11/05/24
Best Analysts Covering Bicara Therapeutics Inc.
1 Month
xxx
Success Rate
7/10 ratings generated profit
Average Return
+1.42%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +1.42% per trade.
3 Months
xxx
Success Rate
4/7 ratings generated profit
Average Return
+15.64%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +15.64% per trade.
1 Year
Success Rate
6/7 ratings generated profit
Average Return
+47.63%
reiterated a buy rating 23 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +47.63% per trade.
2 Years
xxx
Success Rate
6/7 ratings generated profit
Average Return
+47.63%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +47.63% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BCAX Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Aug 25
Sep 25
Strong Buy
9
12
13
12
11
Buy
2
5
5
5
3
Hold
1
2
3
3
2
Sell
2
3
3
1
0
Strong Sell
0
0
0
0
0
total
14
22
24
21
16
Each month's total comprises the sum of three months' worth of ratings.
BCAX Financial Forecast
BCAX Stock Forecast FAQ
What is BCAX’s average 12-month price target, according to analysts?
Based on analyst ratings, Bicara Therapeutics Inc.’s 12-month average price target is 31.67.
What is BCAX’s upside potential, based on the analysts’ average price target?
Bicara Therapeutics Inc. has 75.94% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BCAX a Buy, Sell or Hold?
Bicara Therapeutics Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
What is Bicara Therapeutics Inc.’s price target?
The average price target for Bicara Therapeutics Inc. is 31.67. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $48.00 ,the lowest forecast is $8.00. The average price target represents 75.94% Increase from the current price of $18.
The highest analyst price target is $48.00 ,the lowest forecast is $8.00. The average price target represents 75.94% Increase from the current price of $18.
What do analysts say about Bicara Therapeutics Inc.?
Bicara Therapeutics Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of BCAX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.